Mota Ventures Launching Immune Support CBD Line; Pure Herbal Immunity Blend Acquiring 1,838 New Customers Within a Week
Mota Ventures Corp. (CSE:MOTA, FSE:1WZ:GR, OTC:PEMTF) (the “Company” or “Mota”) is pleased to announce that since the launch of the Pure Herbal Immunity Blend under the First Class brand on March 14th, 2020, it has had an exceptional reception, acquiring 1,838 new customers.
The all-natural Immunity Blend is made from 100% pure essential oils, including cinnamon leaf, lemon, clove bud, lime, eucalyptus globulus, rosemary, peppermint, spearmint and oregano. Due to customer demand for pure and efficacious products to support the immune system, the Company will be launching an Immune CBD oil, along with an Elderberry Gummy product on Monday, March 23rd. The new Immune CBD product contains CBD, B3, B12, Vitamin C and Zinc. Based on the success of the launch, First Class will be increasing marketing efforts throughout the US.
The Company plans to offer similar immune products in Europe through its Sativida brand, which currently retails product in various jurisdictions in Europe, including Spain, Portugal, Austria, Germany, France and the United Kingdom.
The Company anticipates the completion of the Sativida transaction in the next seven days. Further to its January 10, 2020 news release, the Company will acquire the intellectual property and trade names of Sativida from VIDA BCN LABS SL (Spain) and Sativida OU (Estonia) (collectively, “Sativida”). The Company will license both back to Sativida in exchange for a royalty associated with the gross revenues generated by Sativida.
“As our customers around the globe face challenges in their daily lives, we are working diligently to provide products to help families with natural health needs. Our supply chain is operating uninterrupted and we are quickly working to expand our immune support product line. We stand ready to continue to adapt to market changes and innovate new products to take advantage of the numerous opportunities ahead”, states Ryan Hoggan, CEO of the Company.
About Mota Ventures Corp.
Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.
Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain and the United Kingdom. Sativida currently develops and retails a vast range of organic CBD oils and cosmetics across Europe and is currently expanding its distribution network internationally. For more information on Sativida, readers are encouraged to review their website, www.sativida.es.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.
Chief Executive Officer
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to its completion of the acquisition of Sativida, the expansion of Sativida’s business, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/